Fox Jennifer A. 4

What Happened

• Jennifer A. Fox, a director of Apogee Therapeutics, was granted a derivative award on 2026-06-09 representing the right to purchase 7,657 shares of the company's common stock. The Form 4 reports acquisition at $0.00 (derivative award), with no cash exchanged at grant.

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-11 (timely filing).
• Instrument: Option/derivative award for 7,657 shares (reported as Acquisition, Code A).
• Reported acquisition price: $0.00 (award/grant); filing does not specify an exercise price or post-vesting terms beyond the footnote.
• Shares owned after the transaction: not specified in the filing.
• Footnote: The option vests on the one-year anniversary of the grant date, subject to Fox's continued service (F1).
• No indication of a 10b5-1 plan, tax withholding, or sale; this is a grant, not an open-market purchase or sale.

Context

• This is a standard equity grant to a director; the award creates the right to buy shares in the future but does not represent an immediate purchase of stock. Vesting is time-based (one year) and contingent on continued service. Such grants are routine for compensation and do not by themselves indicate an immediate change in insider sentiment.